Further, the value brought by generic, biosimilar and other offpatent competition is increasingly evident by the social disparities in health outcomes across countries and therapeutic areas and as health system resources are constrained by the COVID-response; these off-patent medicines will be an important component of a post-COVID-19 health system as economies increasingly feel the aftershocks of this global pandemic.